Algo version: 0.98b
Kilitch Drugs (India) is listed at the NSE Exchange
Kilitch Drugs (India) [KILITCH.NS]
NSE Sector: Healthcare Industry:Drug Manufacturers—Specialty & Generic

Is Kilitch Drugs (India) stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

Yes, Kilitch Drugs (India) pays dividends. Last time was Wednesday 30th of October 2019 where the investors holding the stock on Friday 20th of September 2019 were paid INR0.5 per share. Over the last 5 times between 2010 and 2019, Kilitch Drugs (India) has paid INR33 with an average of INR6.6 per share.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Kilitch Drugs (India) 10 years ago, but if you had invested on Monday 9th of September 2019 when the price was INR105.15, you would have made a profit of INR235.45 per share or 223.92%

Yes, the average daily trading liquidity for Kilitch Drugs (India) is INR20 946 thousand. You should therefore be able to get in and out of your positions relatively fast.

Kilitch Drugs (India) has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. With a normal cash flow to debt ratio of 0.21, the company's ability to pay off the debt is normal. Kilitch Drugs (India) has a good net profit margin of 9.46% and should have high tolerances against inflation.

We have calculated the inflation risk for Kilitch Drugs (India) to be low [0.4 of 1]

US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.